Repros' Hypogonadism Treatment Enclomiphene Heads To FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Efficacy and safety data for drug, formerly known as Androxal, will be vetted by FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee Nov. 3.